Your monthly Lumakras cost savings if eligible
The Lumakras patient assistance program can provide your medication for free. We simply charge $49 per month for each medication to cover the cost of our services. With NiceRx, you will only pay $49 to obtain your Lumakras, regardless of the retail price.
Am I eligible for the Lumakras patient assistance program?
To find out if you are eligible for Lumakras assistance you can apply online using our enrollment application. Each pharmaceutical company sets its eligibility criteria, and we will review your application individually to determine if you may be eligible. The three main factors to consider are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Lumakras patient assistance program?
Our application process aims to make it as easy as possible to apply for the Lumakras patient assistance program. The first step is to complete our online enrollment application. We will ask you for details about your healthcare provider, your insurance plan, and your household income as this information is required by the pharmaceutical companies. We may be able to help you apply for other patient assistance programs too, so be sure to tell us about any medications you are taking as well as Lumakras.
NiceRx will review your application and determine whether you may be eligible for Lumakras assistance. If so, we will handle the full enrollment process for you and prepare all required documents for your healthcare provider to sign. Once you are successfully enrolled in the Lumakras patient assistance program, we will help you manage your prescription refills by requesting refills on your behalf throughout your enrollment period. At the end of your enrollment period, we will contact you for updated information and seek to re-enroll you so you can continue to access affordable Lumakras.
Is NiceRx a Lumakras coupons provider?
NiceRx is a service provider that helps eligible individuals access the Lumakras patient assistance program. We do not offer trial offers or free Lumakras samples. When obtaining your medication through NiceRx, you will only pay $49 a month per medication. This will likely save you more money than if you were to use Lumakras coupons, discount cards, or Lumakras copay cards.
Can NiceRx help me get Lumakras if I have insurance?
NiceRx may be able to help you if your insurance company will not pay for your Lumakras medication. We may also be able to help if you have a high copay or coinsurance responsibility. Whether you have insurance or not, apply online using our enrollment application to find out more.
How much does Lumakras cost without insurance?
Lumakras prices without insurance will vary depending on how much you buy. Prices will also vary by retailer. As a guide, Lumakras oral tablet 120 mg typically costs $18,700 for 240 tablets.
How much does Lumakras cost with insurance?
The copay for Lumakras will vary by the terms of your healthcare plan. To find out what you might need to pay for Lumakras with insurance, your insurance provider or pharmacist will be able to help you calculate the copay costs with your current insurance.
What is Lumakras?
Lumakras is an FDA-approved (U.S. Food and Drug Administration) medication manufactured by Amgen Inc.
Lumakras is an inhibitor of the RAS GTPase family and is used for the treatment of adult patients with KRAS G12C-mutation locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approval test, who have received at least one prior systemic therapy. This use is approved under accelerated approval based on the overall response rate (ORR) and the duration of response (DOR).
Amgen has partnered with two companies: Guardant Health and Qiagen to develop blood and tissue-based companion diagnostics (CDx), for Lumakras. With these tests, patients and clinicians will have a greater ability for conducting KRAS G12C biomarker testing.
CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C – mutant solid tumors. The primary endpoint for the Phase 2 study was a centrally assessed objective response rate. The Phase 2 trial in colorectal cancer (CRC) is fully enrolled and topline results are expected later in 2021.
What doses of Lumakras are available?
Lumakras is available in tablet form, in the following doses: 120 mg.
The recommended dosage is 960 mg orally once daily. Tablets should be swallowed whole with or without food.
Always speak with your healthcare professional about any changes to your dose so they can monitor and evaluate your condition. Please also see the full prescribing information for Lumakras.
Lumakras active ingredients
Lumakras contains the active ingredient sotorasib. It is an inhibitor of KRASG12C, a tumor-restricted, mutant-oncogenic form of the RAS GTPase, KRAS.
Lumakras side effects
The most common side effects of Lumakras in clinical trials include:
- Diarrhea, nausea
- Joint pain
- Hepatotoxicity – changes in liver function tests
- Decreased lymphocytes, hemoglobin, calcium, sodium
- Increased aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and urine protein
In rare instances, Lumakras can cause more serious adverse events. These can include:
- Interstitial Lung Disease (ILD), pneumonitis – monitor for new or worsening symptoms
Your doctor will assess the benefits of using Lumakras against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Lumakras to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Lumakras drug interactions
Lumakras can interact with other medications. These include:
- Proton pump inhibitors (PPIs) and H2 receptor antagonists – if an acid-reducing agent cannot be avoided, give Lumakras 4 hours before or 10 hours after the antacid
- Strong CYP3A4 Inducers
- CYP3A4 Substrates
- P-gp substrates – avoid P-gp substrates for which minimal concentration changes may cause serious toxicities
This list is not exhaustive and other prescription drugs may interact with Lumakras.
You should not use Lumakras if you:
- Are allergic to the active ingredient sotorasib
- Are allergic to any of the other ingredients in Lumakras
- Are pregnant or are planning to become pregnant
Talk to your doctor before using Lumakras if you:
- Are taking any of the medications that could interact with Lumakras
- Have liver problems
- Have lung or breathing problems other than lung cancer
- Are pregnant or are planning to become pregnant
- Are breastfeeding or plan to breastfeed – do not breastfeed during treatment, and for 1 week after the final dose
Lumakras is the trademark brand name for sotorasib manufactured by Amgen Inc. A generic version of sotorasib is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Lumakras savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.